Successful Use of Intravenous Methylnaltrexone for Opioid-Induced Constipation in Critically Ill Pediatric Patients

Abstract

Objectives Methylnaltrexone is U.S. Food and Drug Administration (FDA) approved as a subcutaneous injection for adults with opioid-induced constipation (OIC). Case series have described the use of methylnaltrexone for OIC in the pediatric oncology population. There are limited data describing its intravenous use in critically ill pediatric patients.

Methods We conducted a retrospective observational study at St. Louis Children's Hospital. Patients less than 18 years old who received at least one dose of intravenous methylnaltrexone while admitted to an intensive care unit between January 2016 and August 2019 were included. The primary outcome was documented laxation within 24 hours of methylnaltrexone administration.

Results Sixteen patients received a total of 34 doses of intravenous methylnaltrexone. Patients received a median of 1.69 (interquartile range [IQR], 0.9–4.86) morphine milligram equivalents per kilogram per 24 hours, over a median of 14 days (IQR, 11–30), before methylnaltrexone administration. The median dose of methylnaltrexone was 0.15 mg/kg (IQR, 0.15–0.16). Ten patients (63%) responded to the first dose of methylnaltrexone, and 14 patients (88%) responded to at least one dose. Overall, 26 doses (76%) led to patient response. Four patients (25%) experienced adverse events (emesis, abdominal pain) after methylnaltrexone administration. No signs or symptoms of opioid withdrawal were documented.

Conclusions Intravenous methylnaltrexone appears to be safe and effective in treating OIC in critically ill pediatric patients. No serious adverse events or signs of opioid withdrawal were observed after single and repeat dosing. Patients responded to methylnaltrexone with varying opioid dosing and durations prior to administration.

Keywords

methylnaltrexone - opioid-induced constipation - intensive care unit - pediatric - Peripherally acting mu-opioid receptor antagonists

Publication History

Received: 15 June 2021

Accepted: 24 August 2021

Article published online:
07 October 2021

• References

• 1 Dorn S, Lembo A, Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Am J Gastroenterol Suppl 2014; 2 (01) 31-37
• 2 Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006; 74 (08) 1347-1354
• 3 Moss J, Rosow CE. Development of peripheral opioid antagonists' new insights into opioid effects. Mayo Clin Proc 2008; 83 (10) 1116-1130
• 4 Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S. American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology 2019; 156 (01) 218-226
• 5 Relistor [package insert], Wyeth Pharmaceuticals Inc and Progenics Pharmaceuticals, Philadelphia, PA, and Tarrytown, NY. 2009
• 6 van der Spoel JI, Oudemans-van Straaten HM, Kuiper MA, van Roon EN, Zandstra DF, van der Voort PH. Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial. Crit Care Med 2007; 35 (12) 2726-2731
• 7 Merchan C, Altshuler D, Papadopoulos J. Methylnaltrexone versus naloxone for opioid-induced constipation in the medical intensive care unit. Ann Pharmacother 2017; 51 (03) 203-208
• 8 Sawh SB, Selvaraj IP, Danga A, Cotton AL, Moss J, Patel PB. Use of methylnaltrexone for the treatment of opioid-induced constipation in critical care patients. Mayo Clin Proc 2012; 87 (03) 255-259
• 9 Woo M, O'Connor M, Yuan CS, Moss J. Reversal of opioid-induced gastric dysfunction in a critically ill burn patient after methylnaltrexone. Anesth Analg 2008; 107 (06) 1965-1967
• 10 Yuan CS, Foss JF, O'Connor M. et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000; 283 (03) 367-372
• 11 Flerlage JE, Baker JN. Methylnaltrexone for opioid-induced constipation in children and adolescents and young adults with progressive incurable cancer at the end of life. J Palliat Med 2015; 18 (07) 631-633
• 12 Kissling KT, Mohassel LR, Heintz J. Methylnaltrexone for opioid-induced constipation in a pediatric oncology patient. J Pain Symptom Manage 2012; 44 (01) e1-e3
• 13 Laubisch JE, Baker JN. Methylnaltrexone use in a seventeen-month-old female with progressive cancer and rectal prolapse. J Palliat Med 2013; 16 (11) 1486-1488
• 14 Rodrigues A, Wong C, Mattiussi A, Alexander S, Lau E, Dupuis LL. Methylnaltrexone for opioid-induced constipation in pediatric oncology patients. Pediatr Blood Cancer 2013; 60 (10) 1667-1670
• 15 Yeomanson D, Chohan O, Mayer A. Paediatric palliative care: intravenous methylnaltrexone relieves constipation. BMJ Support Palliat Care 2013; 3 (01) 103-105
• 16 Collier ZJ, Pham CH, Gillenwater J. First reported use of methylnaltrexone to treat opioid-induced constipation in a pediatric burn patient. J Burn Care Res 2018; 39 (01) S166
• 17 Garten L, Degenhardt P, Bührer C. Resolution of opioid-induced postoperative ileus in a newborn infant after methylnaltrexone. J Pediatr Surg 2011; 46 (03) e13-e15
• 18 López J, Botrán M, García A. et al. Constipation in the critically ill child: frequency and related factors. J Pediatr 2015; 167 (04) 857-861.e1
• 19 Voepel-Lewis T, Zanotti J, Dammeyer JA, Merkel S. Reliability and validity of the face, legs, activity, cry, consolability behavioral tool in assessing acute pain in critically ill patients. Am J Crit Care 2010; 19 (01) 55-61 , quiz 62
• 20 Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain–United States, 2016. JAMA 2016; 315 (15) 1624-1645
• 21 Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online. Waltham, MA: UpToDate, Inc; . Accessed on September 20, 2021 at: https://online.lexi.com
• 22 Arpino PA, Thompson BT. Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit. J Clin Pharm Ther 2009; 34 (02) 171-175
• 23 Gibson CM, Pass SE. Enteral naloxone for the treatment of opioid-induced constipation in the medical intensive care unit. J Crit Care 2014; 29 (05) 803-807
• 24 Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain 2000; 84 (01) 105-109
• 25 Tofil NM, Benner KW, Faro SJ, Winkler MK. The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit. Pediatr Crit Care Med 2006; 7 (03) 252-254
• 26 Mostafa SM, Bhandari S, Ritchie G, Gratton N, Wenstone R. Constipation and its implications in the critically ill patient. Br J Anaesth 2003; 91 (06) 815-819